Gevokizumab: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
No edit summary Tag: Manual revert |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | |||
Latest revision as of 17:11, 22 March 2025
Gevokizumab is a monoclonal antibody designed for the treatment of autoimmune diseases. It was developed by XOMA, a biotechnology company based in the United States.
Mechanism of Action[edit]
Gevokizumab works by binding to and inhibiting the action of interleukin-1 beta, a protein that plays a key role in the inflammatory response of the immune system. By blocking the action of interleukin-1 beta, gevokizumab can help to reduce inflammation and the symptoms of autoimmune diseases.
Clinical Trials[edit]
Gevokizumab has been tested in several clinical trials for a variety of autoimmune diseases, including Behcet's disease, non-infectious uveitis, and pyoderma gangrenosum. The results of these trials have shown that gevokizumab can be effective in reducing the symptoms of these diseases.
Side Effects[edit]
Like all medications, gevokizumab can cause side effects. The most common side effects reported in clinical trials include nausea, headache, and fatigue. In rare cases, gevokizumab can cause serious side effects, such as infection, allergic reactions, and changes in blood cell counts.
Future Developments[edit]
Research is ongoing to further understand the potential benefits and risks of gevokizumab. Future studies may explore the use of gevokizumab in other autoimmune diseases, as well as its potential role in the treatment of other conditions characterized by inflammation.
